全文获取类型
收费全文 | 16995篇 |
免费 | 1064篇 |
国内免费 | 275篇 |
专业分类
耳鼻咽喉 | 340篇 |
儿科学 | 166篇 |
妇产科学 | 258篇 |
基础医学 | 2797篇 |
口腔科学 | 269篇 |
临床医学 | 1486篇 |
内科学 | 3483篇 |
皮肤病学 | 562篇 |
神经病学 | 1262篇 |
特种医学 | 1264篇 |
外科学 | 2099篇 |
综合类 | 43篇 |
现状与发展 | 1篇 |
一般理论 | 3篇 |
预防医学 | 554篇 |
眼科学 | 358篇 |
药学 | 1676篇 |
中国医学 | 271篇 |
肿瘤学 | 1442篇 |
出版年
2024年 | 3篇 |
2023年 | 129篇 |
2022年 | 496篇 |
2021年 | 701篇 |
2020年 | 350篇 |
2019年 | 515篇 |
2018年 | 595篇 |
2017年 | 490篇 |
2016年 | 777篇 |
2015年 | 1055篇 |
2014年 | 1146篇 |
2013年 | 1263篇 |
2012年 | 1858篇 |
2011年 | 1733篇 |
2010年 | 1015篇 |
2009年 | 804篇 |
2008年 | 1061篇 |
2007年 | 938篇 |
2006年 | 786篇 |
2005年 | 676篇 |
2004年 | 476篇 |
2003年 | 446篇 |
2002年 | 392篇 |
2001年 | 132篇 |
2000年 | 121篇 |
1999年 | 83篇 |
1998年 | 59篇 |
1997年 | 34篇 |
1996年 | 23篇 |
1995年 | 25篇 |
1994年 | 24篇 |
1993年 | 25篇 |
1992年 | 23篇 |
1991年 | 9篇 |
1990年 | 9篇 |
1989年 | 8篇 |
1988年 | 6篇 |
1987年 | 11篇 |
1986年 | 5篇 |
1985年 | 6篇 |
1984年 | 6篇 |
1983年 | 2篇 |
1982年 | 3篇 |
1981年 | 4篇 |
1980年 | 7篇 |
1979年 | 1篇 |
1977年 | 1篇 |
1974年 | 1篇 |
1966年 | 1篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
71.
Sung Yeon Kim Y R Santosh Laxmi Naomi Suzuki Kenichiro Ogura Tadashi Watabe Michael W Duffel Shinya Shibutani 《Drug metabolism and disposition》2005,33(11):1673-1678
Tamoxifen (TAM) is used as the standard endocrine therapy for breast cancer patients and as a chemopreventive agent for women at high risk for this disease. Unfortunately, treatment of TAM increases the incidence of endometrial cancer; this may be due to the genotoxic damage induced by TAM metabolites. Formation of TAM-DNA adducts in rat liver correlates with the development of hepatocarcinoma. TAM-DNA adducts are proposed to be formed through O-sulfonation and/or O-acetylation of alpha-hydroxylated TAM and its metabolites. However, the role of O-sulfonation and O-acetylation in the formation of TAM-DNA adducts has not been extensively investigated. Rat or human hydroxysteroid sulfotransferases (HST), acetyltransferases, and liver cytosol were incubated with calf thymus DNA, alpha-OHTAM, and either 3'-phosphoadenosine 5'-phosphosulfate (PAPS) or acetyl coenzyme A (acetyl-CoA) as a cofactor and analyzed for TAM-DNA adduct formation, using 32P postlableling/polyacrylamide gel electrophoresis analysis. TAM-DNA adduct was formed when PAPS, not acetyl-CoA, was used. No TAM-DNA adducts were produced using human N-acetyltransferase I and II. HST antibody inhibited approximately 90% of TAM-DNA adduct formation generated by the cytosol or HST, suggesting that HST is primarily involved in the formation of TAM-DNA adducts. The formation of TAM-DNA adducts with rat liver cytosol and HST was much higher than that of human liver cytosol and HST. Our results indicate that TAM-DNA adducts are formed via O-sulfonation, not O-acetylation, of alpha-hydroxylated TAM and its metabolites. 相似文献
72.
73.
Vascular endothelial growth factor gene polymorphisms and risk of primary lung cancer. 总被引:17,自引:0,他引:17
Su Jeong Lee Sin Yeob Lee Hyo-Sung Jeon Sun Ha Park Jin Sung Jang Ga Young Lee Ji Woong Son Chang Ho Kim Won Kee Lee Sin Kam Rang Woon Park Tae-In Park Young Mo Kang In-San Kim Tae Hoon Jung Jae Yong Park 《Cancer epidemiology, biomarkers & prevention》2005,14(3):571-575
Angiogenesis is an essential process in the development, growth, and metastasis of malignant tumors including lung cancer. DNA sequence variations in the vascular endothelial growth factor (VEGF) gene may lead to altered VEGF production and/or activity, thereby causing interindividual differences in the susceptibility to lung cancer via their actions on the pathways of tumor angiogenesis. To test this hypothesis, we investigated the potential association between three VEGF polymorphisms (-460T > C, +405C > G, and 936C > T)/haplotypes and the risk of lung cancer in a Korean population. VEGF genotypes were determined in 432 lung cancer patients and 432 healthy controls that were frequency matched for age and sex. VEGF haplotypes were predicted using Bayesian algorithm in the phase program. Compared with the combined +405 CC and CG genotype, the +405 GG genotype found associated with a significantly decreased risk of small cell carcinoma [SCC; adjusted odds ratio (OR), 0.36; 95% confidence interval (95% CI), 0.17-0.78]. The 936 CT genotype and the combined 936 CT and TT genotype were also associated with a significantly decreased risk of SCC compared with the 936 CC genotype (adjusted OR, 0.47; 95% CI, 0.26-0.85 and adjusted OR, 0.44; 95% CI, 0.24-0.80, respectively). Haplotype CGT was associated with a significantly decreased risk of SCC (adjusted OR, 0.39; 95% CI, 0.18-0.87), whereas haplotype TCC conferred a significantly increased risk of SCC (adjusted OR, 1.63; 95% CI, 1.14-2.33). None of the VEGF polymorphisms studied significantly influenced the susceptibility to lung cancer except SCC. However, haplotypes TCT and TGT were significantly associated with the risk of overall lung cancer, respectively (adjusted OR, 0.38; 95% CI, 0.25-0.60 and adjusted OR, 3.94; 95% CI, 2.00-7.76, respectively). These effects of haplotypes TCT and TGT on lung cancer risk were observed in three major histologic types of lung cancer. These results suggest that the VEGF gene may be contribute to an inherited predisposition to lung cancer. 相似文献
74.
75.
76.
77.
Nevus sebaceous (NS) is a common congenital hamartoma of the skin composed predominantly of sebaceous glands. Although most NS are benign skin tumors, malignant transformations have been reported. There is still controversy about the lifetime risk of malignant degeneration and precise surgical criteria. This study reports cases of malignant degeneration and suggests a surgical treatment algorithm. The medical records of patients with basal-cell carcinoma (BCC) arising from NS between January 2001 and January 2021 were retrospectively reviewed. Patient demographics including lesion location, and tumor size were investigated. The symptoms, histological findings before and after excision, complications, and recurrence during 2-year follow-up periods were investigated. Ten patients were identified with BCC arising from NS lesions. All patients were female and the mean age was 52.11 years. All patients complained of sudden morphological changes, the most common type being rapid color changes. Two cases had histological findings that showed a miss-match between punch biopsy and excisional biopsy results. No recurrence was detected 2 years after surgeries in any patients. Cases after third stage, especially in over 40 years who report morphologic changes, should undergo total surgical excision as the first approach, with strong suspicion of malignant degeneration. 相似文献
78.
Jun-Pil Jang Gil Soo Kim Tae Hoon Oh Beomcheol Park Minhee Kim Gwi Ja Hwang Hyeok-Won Lee Jin-Gyeom Lee Young-Soo Hong Jong Seog Ahn Sung-Kyun Ko Jae-Hyuk Jang 《RSC advances》2022,12(35):22360
Two new polyketide glycosides jejuketomycins A (1) and B (2), were isolated from a culture of Streptomyces sp. KCB15JA151. Their chemical structures including the absolute configurations were determined by detailed analyses of the NMR and HRMS data and ECD calculations and spectral data. Compounds 1 and 2 possess an unusual 6/6/8 tricyclic ring system. Biological evaluation with the wound healing assay and time-lapse cell tracking analysis revealed that compounds 1 and 2 have significant inhibitory activities against cancer cell migration with low cytotoxicity.Two new polyketide glycosides jejuketomycins A (1) and B (2), were isolated from a culture of Streptomyces sp. KCB15JA151. 相似文献
79.
80.
Sung Uk Lee Jinsil Seong Tae Hyun Kim Jung Ho Im Woo Chul Kim Kyubo Kim Hae Jin Park Tae Gyu Kim Youngkyong Kim Bae Kwon Jeong Jin Hee Kim Byoung Hyuck Kim Taek-Keun Nam 《癌症生物学与医学(英文版)》2022,19(6):931
Objective:The effectiveness of adjuvant treatments for resected gallbladder carcinoma (GBC) has remained unclear due to lack of randomized controlled trials; thus, the aim of present study was to evaluate the role of adjuvant treatments, including chemoradiotherapy (CRT) and/or chemotherapy (CTx), in patients with resected GBC.Methods:A total of 733 GBC patients who received curative-intent surgical resection were identified in a multi-institutional database. Of 733 patients, 372 (50.8%) did not receive adjuvant treatment, whereas 215 (29.3%) and 146 (19.9%) received adjuvant CTx and CRT, respectively. The locoregional recurrence-free survival (LRFS), recurrence-free survival (RFS), and overall survival (OS) of the adjuvant treatment groups were compared according to tumor stage (stage II vs. stage III–IV).Results:In stage II disease (n = 381), the 5-year LRFS, RFS, and OS were not significantly different among the no-adjuvant therapy, CTx, and CRT groups, and positive resection margin, presence of perineural invasion, and Nx classification were consistently associated with worse LRFS, RFS, and OS in the multivariate analysis (P < 0.05). For stage III–IV (n = 352), the CRT group had significantly higher 5-year LRFS, RFS, and OS than the no-adjuvant therapy and CTx groups (67.8%, 45.2%, and 56.9%; 37.9%, 28.8%, and 35.4%; and 45.0%, 30.0%, and 45.7%, respectively) (P < 0.05).Conclusions:CRT has value as adjuvant treatment for resected GBC with stage III–IV disease. Further study is needed for stage II disease with high-risk features. 相似文献